A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation.
Research article published in Journal of thrombosis and thrombolysis (2014)
Abstract
The use of novel anticoagulants such as dabigatran are increasing. Despite increased risks of intracerebral haemorrhage with warfarin among Asians, there is little published data on dabigatran to assess 'real world' efficacy and safety of dabigatran therapy in Asia. This was a retrospective observational study of patients prescribed dabigatran between 2010 and 2013. Data was available for 510 patients: median age 68 years (range 20-91), median CHA2DS2-VASc score was 2 and median HAS-BLED score was 2. The average follow-up duration of 315 days (range: 1-1,096). The overall discontinuation rate was 16% after a median 252 days of treatment with dabigatran. There were 17 (3.3%) patients with minor bleeding, 2 (0.4%) had major bleeding episodes. 20 patients (3.9%) developed dyspepsia which was the most common side effect. The rate of occurrences of adverse effects and bleeding were lower than those seen in the RE-LY trial. None of the patients had an ischaemic stroke, 1 (0.2%) patient had a haemorrhagic stroke. Out of 510 patients, 158 patients (31%) were switched to dabigatran from warfarin. This showed that patients frequently preferred the dabigatran due to convenience when given a choice to switch from warfarin. We report one of the largest registry of Asian patients. Reassuringly, we found that our cohort had a low rate of rate of ischaemic stroke, low rates of side effects and bleeding with the drug.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation.
Warum dies für die Hirudotherapie relevant ist
Diese retrospektive Beobachtungsstudie berichtet über Erfahrungen aus der Praxis mit Dabigatran bei 510 Patienten (medianes Alter 68 Jahre), denen das Medikament zwischen 2010 und 2013 verordnet wurde, mit einer mittleren Nachbeobachtungsdauer von 315 Tagen. Die Studie ergab keine ischämischen Schlaganfälle, geringe Raten schwerer Blutungen (0,4 %), eine Abbruchrate von 16 % sowie Dyspepsie als häufigste Nebenwirkung (3,9 %). Dabigatran ist zwar ein direkter Thrombin-Inhibitor und der Artikel ist in MeSH unter "Antithrombins" indexiert, der Abstract erwähnt jedoch weder Blutegel, Hirudotherapie noch von Blutegeln stammende Verbindungen. Die Studie befasst sich ausschließlich mit pharmazeutischen Antikoagulationsergebnissen, und die Relevanz für das ASH-Gebiet ist vernachlässigbar, ohne vertretbare Verbindung zu Blutegeln.
Zitation
A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation.
Yap et al. · Journal of thrombosis and thrombolysis, 2014
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026